These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 31086307)

  • 41. Late Onset Pompe Disease with Novel Mutations and Atypical Phenotypes.
    Chawla T; Preethish-Kumar V; Polavarapu K; Vengalil S; Bardhan M; Puri R; Verma J; Christopher R; Supriya M; Nashi S; Prasad C; Nadeesh B; Nalini A
    J Neuromuscul Dis; 2022; 9(2):261-273. PubMed ID: 34864681
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The earliest enzyme replacement for infantile-onset Pompe disease in Japan.
    Tocan V; Mushimoto Y; Kojima-Ishii K; Matsuda A; Toda N; Toyomura D; Hirata Y; Sanefuji M; Sawada T; Sakai Y; Nakamura K; Ohga S
    Pediatr Int; 2022 Jan; 64(1):e15286. PubMed ID: 36074069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
    Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
    Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease.
    Gupta N; Kazi ZB; Nampoothiri S; Jagdeesh S; Kabra M; Puri RD; Muranjan M; Kalaivani M; Rehder C; Bali D; Verma IC; Kishnani PS
    J Pediatr; 2020 Jan; 216():44-50.e5. PubMed ID: 31606152
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An integrative correlation of myopathology, phenotype and genotype in late onset Pompe disease.
    Kulessa M; Weyer-Menkhoff I; Viergutz L; Kornblum C; Claeys KG; Schneider I; Plöckinger U; Young P; Boentert M; Vielhaber S; Mawrin C; Bergmann M; Weis J; Ziagaki A; Stenzel W; Deschauer M; Nolte D; Hahn A; Schoser B; Schänzer A
    Neuropathol Appl Neurobiol; 2020 Jun; 46(4):359-374. PubMed ID: 31545528
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
    Diaz-Manera J; Kishnani PS; Kushlaf H; Ladha S; Mozaffar T; Straub V; Toscano A; van der Ploeg AT; Berger KI; Clemens PR; Chien YH; Day JW; Illarioshkin S; Roberts M; Attarian S; Borges JL; Bouhour F; Choi YC; Erdem-Ozdamar S; Goker-Alpan O; Kostera-Pruszczyk A; Haack KA; Hug C; Huynh-Ba O; Johnson J; Thibault N; Zhou T; Dimachkie MM; Schoser B;
    Lancet Neurol; 2021 Dec; 20(12):1012-1026. PubMed ID: 34800399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
    Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease.
    Laforêt P; Laloui K; Granger B; Hamroun D; Taouagh N; Hogrel JY; Orlikowski D; Bouhour F; Lacour A; Salort-Campana E; Penisson-Besnier I; Sacconi S; Zagnoli F; Chapon F; Eymard B; Desnuelle C; Pouget J;
    Rev Neurol (Paris); 2013; 169(8-9):595-602. PubMed ID: 24008051
    [TBL] [Abstract][Full Text] [Related]  

  • 50. White matter lesions in treated late onset Pompe disease are not different to matched controls.
    Schneider I; Hensel O; Zierz S
    Mol Genet Metab; 2019 Jun; 127(2):128-131. PubMed ID: 31153821
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
    Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
    Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genotype-phenotype correlation of 17 cases of Pompe disease in Spanish patients and identification of 4 novel GAA variants.
    Hernández-Arévalo P; Santotoribio JD; Delarosa-Rodríguez R; González-Meneses A; García-Morillo S; Jiménez-Arriscado P; Guerrero JM; Macher HC
    Orphanet J Rare Dis; 2021 May; 16(1):233. PubMed ID: 34020684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel GAA mutations in patients with Pompe disease.
    Turaça LT; de Faria DO; Kyosen SO; Teixeira VD; Motta FL; Pessoa JG; Rodrigues E Silva M; de Almeida SS; D'Almeida V; Munoz Rojas MV; Martins AM; Pesquero JB
    Gene; 2015 Apr; 561(1):124-31. PubMed ID: 25681614
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.
    Khan AA; Case LE; Herbert M; DeArmey S; Jones H; Crisp K; Zimmerman K; ElMallah MK; Young SP; Kishnani PS
    Genet Med; 2020 May; 22(5):898-907. PubMed ID: 31904026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study.
    Tard C; Bouhour F; Michaud M; Beltran S; Fournier M; Demurger F; Lagrange E; Nollet S; Sacconi S; Noury JB; Magot A; Cintas P; Renard D; Deibener-Kaminsky J; Lefeuvre C; Davion JB; Salort-Campana E; Arrassi A; Taouagh N; Spinazzi M; ; Attarian S; Laforêt P
    Eur J Neurol; 2024 Jul; 31(7):e16292. PubMed ID: 38587143
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of two novel variants in GAA underlying infantile-onset Pompe disease in two Pakistani families.
    Ullah A; Zubaida B; Cheema HA; Naeem M
    J Pediatr Endocrinol Metab; 2020 Apr; 33(4):553-556. PubMed ID: 32049654
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disparities in late and lost: Pediatricians' role in following Pompe disease identified by newborn screening.
    Pillai NR; Fabie NAV; Kaye TV; Rosendahl SD; Ahmed A; Hietala AD; Jorgenson AB; Lanpher BC; Whitley CB
    Mol Genet Metab; 2023; 140(1-2):107633. PubMed ID: 37414610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
    Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
    Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.
    Schoser B; Stewart A; Kanters S; Hamed A; Jansen J; Chan K; Karamouzian M; Toscano A
    J Neurol; 2017 Apr; 264(4):621-630. PubMed ID: 27372449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Newborn screening for Pompe disease in Japan: report and literature review of mutations in the GAA gene in Japanese and Asian patients.
    Momosaki K; Kido J; Yoshida S; Sugawara K; Miyamoto T; Inoue T; Okumiya T; Matsumoto S; Endo F; Hirose S; Nakamura K
    J Hum Genet; 2019 Aug; 64(8):741-755. PubMed ID: 31076647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.